Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance

Immune checkpoint blockade has reshaped the treatment landscape of advanced hepatocellular carcinoma (HCC), yet durable responses remain limited to a subset of patients. Increasing evidence indicates that therapeutic resistance cannot be explained solely by T-cell exhaustion or PD-1/PD-L1 expression, but is actively shaped by an interconnected myeloid ecosystem. In HCC, tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs) integrate signals from oncogenic pathways, chronic liver injury, fibrosis, metabolic stress, vascular remodeling, and therapy-induced damage. TAM subsets such as TREM2⁺, MARCO⁺, and CX3CR1⁺ macrophages promote CD8⁺ T-cell exclusion, suppress innate immune sensing, and form spatially protected tumor niches. TANs contribute to immune escape through immunosuppressive neutrophil states, neutrophil extracellular traps, CD73–adenosine signaling, and direct impairment of CD8⁺ T cells. MDSCs expand in response to radiofrequency ablation, chemotherapy resistance, fibrosis-associated inflammation, and immune checkpoint pressure, reinforcing PD-L1-, VEGF-A-, S100A9-, and TGF-β-related suppression. This review summarizes recent experimental evidence defining macrophage–neutrophil–MDSC crosstalk in HCC immune escape and immunotherapy resistance. We also discuss how other therapeutic pressures, including locoregional therapy and chemotherapy, can reshape the myeloid ecosystem and thereby influence subsequent immune control. Finally, we highlight myeloid-targeted strategies, biomarker development, etiology-informed stratification, and ecosystem-guided combinations aimed at improving immunotherapy outcomes in HCC.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-14
DOI
https://doi.org/10.1016/j.tranon.2026.103117
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance

CHEN Meiqi, wenshi ou, Xingpeng Lin, Yuhai Hu
Translational Oncology
Immune cells in cancer
article

Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance

CHEN Meiqi, wenshi ou, Xingpeng Lin, Yuhai Hu
article en

Abstract

Immune checkpoint blockade has reshaped the treatment landscape of advanced hepatocellular carcinoma (HCC), yet durable responses remain limited to a subset of patients. Increasing evidence indicates that therapeutic resistance cannot be explained solely by T-cell exhaustion or PD-1/PD-L1 expression, but is actively shaped by an interconnected myeloid ecosystem. In HCC, tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs) integrate signals from oncogenic pathways, chronic liver injury, fibrosis, metabolic stress, vascular remodeling, and therapy-induced damage. TAM subsets such as TREM2⁺, MARCO⁺, and CX3CR1⁺ macrophages promote CD8⁺ T-cell exclusion, suppress innate immune sensing, and form spatially protected tumor niches. TANs contribute to immune escape through immunosuppressive neutrophil states, neutrophil extracellular traps, CD73–adenosine signaling, and direct impairment of CD8⁺ T cells. MDSCs expand in response to radiofrequency ablation, chemotherapy resistance, fibrosis-associated inflammation, and immune checkpoint pressure, reinforcing PD-L1-, VEGF-A-, S100A9-, and TGF-β-related suppression. This review summarizes recent experimental evidence defining macrophage–neutrophil–MDSC crosstalk in HCC immune escape and immunotherapy resistance. We also discuss how other therapeutic pressures, including locoregional therapy and chemotherapy, can reshape the myeloid ecosystem and thereby influence subsequent immune control. Finally, we highlight myeloid-targeted strategies, biomarker development, etiology-informed stratification, and ecosystem-guided combinations aimed at improving immunotherapy outcomes in HCC.

Translational OncologyVol. 75
Fujian Medical University (CN), First Affiliated Hospital of Fujian Medical University (CN), Union Hospital (CN)
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon